Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.50
Bid: 40.00
Ask: 41.00
Change: 0.50 (1.25%)
Spread: 1.00 (2.50%)
Open: 40.00
High: 40.50
Low: 40.00
Prev. Close: 40.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Lloyds Pharmacy to list UltraDEX in UK

4 Jun 2018 07:00

RNS Number : 1086Q
Venture Life Group PLC
04 June 2018
 

Venture Life Group plc

("Venture Life" or the "Company")

 

Lloyds Pharmacy to list UltraDEX in UK

New international partnering deal signed

 

Venture Life (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, announces an update on the UltraDEX brand and a new international distribution agreement for the Myco Clear brand.

 

The Company announces the launch of UltraDEX in Lloyds Pharmacy in the UK from 18 June 2018. Initially, this will bring the brand an additional 580 new listings through the introduction in stores of UltraDEX Oral Rinse and UltraDEX Fresh Breath spray. In addition, Lloyds Pharmacy will list these two products, plus the UltraDEX Toothpaste in their online store, where it will be available to purchase online or via click and collect in store.

 

Lloyds Pharmacy is a leading community pharmacy and healthcare provider with over 1,500 pharmacies across the UK, mainly in community and health centre locations.

 

In addition, and as previously announced, Superdrug is launching the new UltraDEX One GOÔ range in 797 stores in the UK from 4 June 2018. UltraDEX One GOÔ is a new and innovative line extension from the Company, providing single use sachets of the clinically proven UltraDEX mouthwash.

 

Separately, the Company also announces a new distribution deal with the international pharmaceutical company Jaba Recordati S.A. ("Jaba") in Portugal for Myco Clear™, a range that helps treat and prevent nail fungal infections. Launch will take place later this year, or Q1 2019.

 

Commenting Chief Executive Officer, Jerry Randall, said: "I am delighted that we have now been able to get the UltraDEX range into Lloyds Pharmacy, the second largest chain of pharmacies in the UK. Our store listings are now 20% higher than one year ago - this reflects the continued commercial development of the UltraDEX brand in the UK. This increase of distribution also illustrates the growing momentum of the brand along with the launch of the new UltraDEX One GOÔ in Superdrug. We have seen a high level of interest in the new products developed for the UltraDEX range and expect to provide further news in this area soon."

 

I am also delighted to announce the new distribution agreement of Myco Clear with Jaba, who are a significant player in the European OTC market. This opportunity adds to a number of products we already supply to the Recordati Group. The adoption of Myco Clear by such a prestigious company validates the innovative and high quality nature of our products in this area."

 

 

 For further information please contact:

 

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson / Edward Hutton (Corporate Finance)

John Howes / Vadim Alexandre (Corporate Broking) 

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope / Ben Turner

Walbrook PR

venturelife@walbrookpr.com or + 44 (0) 20 7933 8780

Anna Dunphy /Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMMGGVRMDGRZM
Date   Source Headline
7th Oct 201910:57 amRNSHolding(s) in Company
20th Sep 20197:00 amRNSHalf-year Report - Amendment
19th Sep 20197:00 amRNSInterim Results
17th Jul 20197:00 amRNSCommercial update
11th Jul 20193:33 pmRNSDirector/PDMR Shareholding
8th Jul 20195:02 pmRNSHolding(s) in Company
25th Jun 20198:44 amRNSDirector/PDMR Shareholding
3rd Jun 201911:36 amRNSResult of AGM
17th May 20194:35 pmRNSPrice Monitoring Extension
1st May 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSFinal Results
26th Mar 20195:17 pmRNSHolding(s) in Company
20th Mar 20197:00 amRNSNotice of Results Update
29th Jan 20197:00 amRNSTrading and Commercial Update
5th Dec 20183:26 pmRNSHolding(s) in Company
5th Dec 20188:12 amRNSHolding(s) in Company
23rd Nov 20187:00 amRNSChange of adviser and directorate update
15th Nov 20187:00 amRNSCommercial update
20th Sep 20187:01 amRNSDirectorate Change
20th Sep 20187:00 amRNSHalf-year Report
16th Aug 20187:00 amRNSTrading update & notice of interim results
13th Aug 201812:17 pmRNSHolding(s) in Company
8th Aug 20182:15 pmRNSHolding(s) in Company
8th Aug 20187:00 amRNSCompletion of Placing and Acquisition
7th Aug 20184:54 pmRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201810:10 amRNSHolding(s) in Company
6th Aug 201811:51 amRNSResult of General Meeting
23rd Jul 20184:00 pmRNSHolding(s) in Company
20th Jul 20187:00 amRNSPlacing, proposed acquisition and notice of GM
20th Jul 20187:00 amRNSAppointment of Joint Broker
19th Jul 20183:38 pmRNSHolding(s) in Company
18th Jun 20187:00 amRNSIncreased distribution of UltraDEX in Boots, UK
4th Jun 20187:00 amRNSLloyds Pharmacy to list UltraDEX in UK
23rd May 201812:29 pmRNSResult of AGM
21st May 20187:00 amRNS'1000 Companies to Inspire Britain' 2018 report
9th May 20187:00 amRNSAlliance Pharma contract expansion and extension
8th May 20182:54 pmRNSHolding(s) in Company
30th Apr 20187:00 amRNSUltraDEX update
17th Apr 20187:00 amRNSDirector/PDMR Shareholding
5th Apr 20187:00 amRNSDirector/PDMR Shareholding
27th Mar 20187:00 amRNSDirector/PDMR Shareholding
26th Mar 20187:00 amRNS2018 LTIP and Grant of Options to PDMRs
22nd Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of analyst & investor results briefings
16th Feb 20187:00 amRNSInvestor presentation
13th Feb 20187:00 amRNSCommerical update
31st Jan 20187:00 amRNSTrading update
8th Jan 20187:00 amRNSEuropean Business Awards 'Ones to Watch List'

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.